Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR Firm Intellia Prices IPO at $16 to $18 Per Share

NEW YORK (GenomeWeb) – Intellia Therapeutics has priced shares for its upcoming initial public offering in the range of $16 to $18, according to an amendment to its preliminary prospectus filed today with the US Securities and Exchange Commission.

The Cambridge, Massachusetts-based CRISPR/Cas9 gene-editing firm also announced in the amended prospectus that it will offer 5 million shares of common stock in the IPO, and that the Novartis Institutes for Biomedical Research has agreed to concurrently purchase $5 million in common stock in a separate private placement at a price equal to the offering price.

Intellia had previously announced that Regeneron Pharmaceuticals would purchase $50 million in stock in a similar private placement.

The share pricing places a $90 million ceiling on the offering, though the company is also making 750,000 shares available to the IPO underwriters which would bring the total value to no more than $103.5 million.

Intellia filed is preliminary prospectus with the SEC on April 9.

According to that filing, the firm had $75.8 million in cash and cash equivalents and $66.9 million in working capital as of Dec. 31, 2015.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.